US-listed company LIXTE Biotechnology launches crypto reserve strategy, plans to allocate 25% of funds to BTC
According to ChainCatcher, Nasdaq-listed company LIXTE Biotechnology has announced that its board of directors has approved a strategic capital allocation plan to acquire cryptocurrencies as part of the company’s funds. The board has also approved allocating 25% of its funds to cryptocurrencies, including Bitcoin and potentially other digital assets as appropriate.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Two Casascius physical coins dormant for 13 years suddenly moved, with 2,000 BTC transferred
Data: The average cash cost to mine one bitcoin has reached $74,600
A whale opened a 20x leveraged long position on 20,000 ETH at an average price of $3,040.
Trending news
MoreCrypto prices
More
